Related Experiment Video

Updated: Jun 23, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Who does not need a statin: too late in end-stage renal disease or heart failure?

U Laufs1, F Custodis, M Böhm

  • 1Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany. ulrich@laufs.com

Postgraduate Medical Journal
|May 7, 2009
PubMed

Insights

Current guidelines recommend statin drugs for type 2 diabetes and after myocardial infarction. However, statins show limited mortality benefits in elderly heart failure patients and those with end-stage renal disease, suggesting benefits are tied to preventing coronary artery disease progression.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Current guidelines advocate statin therapy for type 2 diabetes and post-myocardial infarction patients.
  • Recent trials (4D, CORONA) indicate statins do not improve mortality in elderly ischemic heart failure or diabetic end-stage renal disease patients on dialysis.

Purpose of the Study:

  • To evaluate the efficacy of statin treatment in specific patient populations.
  • To determine the primary source of survival benefit from statin therapy.
  • To provide guidance on continuing or withdrawing statin treatment in complex cases.

Main Methods:

  • Review of current guidelines and findings from large randomized trials (4D, CORONA).
  • Analysis of survival benefits attributed to statin therapy based on underlying causes of death.
  • Assessment of the role of coronary artery disease progression in statin efficacy.

Main Results:

  • Statin survival benefits are primarily linked to preventing coronary artery disease progression.
  • Statins demonstrate reduced effectiveness when coronary artery disease is not a major cause of mortality.
  • Early initiation of statin treatment is crucial for patients at risk of organ damage.

Conclusions:

  • Statin therapy should be initiated early in patients at risk of organ damage.
  • The effect of statin withdrawal in ischemic heart failure or advanced renal disease remains unknown.
  • Based on current evidence, current statin treatment should not be discontinued in these patient groups.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.